TBRG:NASDAQTruBridge, Inc. Analysis
Data as of 2026-05-04 - not real-time
$25.74
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TruBridge (TBRG) is trading at $25.74, comfortably above its 20‑day ($22.79), 50‑day ($19.38) and 200‑day ($20.43) simple moving averages, indicating a short‑term bullish bias. However, the 14‑day RSI of 82 places the stock in overbought territory and the price is hugging the near‑term resistance level of $25.85, suggesting limited upside in the immediate horizon. The MACD remains bullish with a modest histogram (+0.20), and volume is on an upward trend, supporting the recent price strength. On the valuation side, the trailing P/E of 88.8 dwarfs the industry average of 25.5, while the DCF‑derived fair value of $16.87 implies the market is pricing the stock at a roughly 53% premium, flagging a clear overvaluation signal. Forward earnings estimates paint a different picture: a projected EPS of $2.91 translates to a forward P/E of 8.8, hinting at significant earnings growth potential if the company can execute its roadmap.
Fundamentally, TruBridge delivers modest profitability (operating margin 1.97%, net margin 1.26%) and solid cash generation (operating cash flow $36.9M, free cash flow $29.6M), but carries a high debt load (Debt/Equity 93.7) and faces multiple securities‑fraud investigations reported in recent news, adding regulatory and legal headwinds. The stock shows high 30‑day volatility (≈67%) and a beta near market neutrality (0.95), reinforcing a risk‑aware stance. Given the overvalued price, overbought technicals, and pending legal concerns, a cautious short‑term hold is prudent, while the strong forward earnings outlook and cash flow support a more optimistic medium‑ to long‑term view if price corrections bring valuation back in line with fundamentals.
Fundamentally, TruBridge delivers modest profitability (operating margin 1.97%, net margin 1.26%) and solid cash generation (operating cash flow $36.9M, free cash flow $29.6M), but carries a high debt load (Debt/Equity 93.7) and faces multiple securities‑fraud investigations reported in recent news, adding regulatory and legal headwinds. The stock shows high 30‑day volatility (≈67%) and a beta near market neutrality (0.95), reinforcing a risk‑aware stance. Given the overvalued price, overbought technicals, and pending legal concerns, a cautious short‑term hold is prudent, while the strong forward earnings outlook and cash flow support a more optimistic medium‑ to long‑term view if price corrections bring valuation back in line with fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought territory (82)
- Price near resistance at $25.85
- Ongoing securities‑fraud investigations
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Forward EPS growth to $2.91 (forward P/E 8.8)
- Strong operating and free cash flow generation
- Resolution of legal/regulatory issues could unlock value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Healthcare information services sector tailwinds
- Potential price correction toward DCF fair value (~$16.9)
- Robust cash generation and low dividend reliance
Key Metrics & Analysis
Financial Health
Profit Margin1.26%
P/E Ratio88.8
ROE2.52%
ROA3.94%
Debt/Equity93.70
P/B Ratio2.1
Op. Cash Flow$37.0M
Free Cash Flow$29.6M
Industry P/E25.5
Technical Analysis
TrendNeutral
RSI82.4
Support$16.99
Resistance$25.85
MA 20$22.79
MA 50$19.38
MA 200$20.43
MACDBullish
VolumeIncreasing
Fear & Greed Index88.54
Valuation
Fair Value$16.87
Target Price$25.67
Upside/Downside-0.28%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.95
Volatility67.40%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.